Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparo… (NCT07554040) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery
526 participantsStarted 2026-05-10
Plain-language summary
This study aims to focus on patients undergoing gynecological laparoscopic surgery and further evaluate the role of amisulpride in preventing postoperative nausea and vomiting in these patients.
Who can participate
Age range18 Years – 75 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. 18\<BMI≤30kg/m2 2. Patients scheduled to undergo gynecological laparoscopic surgery (e.g., ovary, fallopian tube, uterus, and gynecological tumors, etc., with an expected surgery duration of ≤3 hours)
Exclusion Criteria:
* 1\. ASA class IV or above 2. Long-term use of opioid drugs or non-steroidal anti-inflammatory drugs 3. Undergoing radiotherapy and chemotherapy 4.Allergic to the medication used 5.Pregnant or breastfeeding women 6.Previously existing vestibular disorders or chronic dizziness, easily nauseous 7.Recent use of antiemetic drugs or prophylactic antiemetic regimen (within 7 days before surgery) 8.Presence of neurological or psychiatric disorders, or cognitive impairment
What they're measuring
1
Complete remission (CR) rate within 24 hours postoperatively
Timeframe: 1 day
Trial details
NCT IDNCT07554040
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University